$0.28
+0.02 (+7.54%)
Last updated: Apr 16, 2026 01:11
Fundamentals Overview
Sangamo Therapeutics, Inc. is near the low of its 52-week range with moderate valuation, showing strong upward momentum today.
Valuation moderate
Risk (Beta)
1.5 — higher vol
BullzEye Analysis
Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Supporting (Buy):
Analyst grade: B-
Pressures (Sell):
Sentiment weakening (1 downgrade) · 3M vs S&P 500: -39.4% · 3M vs Healthcare sector: -32.6% · Beta 1.5 (elevated)
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Overall rating: B-. Recent institutional grades: majority downgrades. Current institutional positions: Buy: 24, Equal Weight: 2, Overweight: 2, Sector Perform: 2.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $-1.08; current price is $0.28. That’s a -493.7% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | N/A |
| PEG (TTM) | N/A |
| P/B (TTM) | N/A |
| P/S (TTM) | 2.88 |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 0.84 |
| Quick Ratio (TTM) | 0.84 |
| Cash Ratio (TTM) | 0.49 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | -3.11% |
| Gross margin (TTM) | 80.78% |
| Operating margin (TTM) | -2.73% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for SGMO.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Buy | 2026-02-10 |
| Barclays | downgrade | Overweight | Equal Weight | 2025-11-07 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-09-04 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-06-24 |
| Barclays | maintain | Overweight | Overweight | 2025-05-14 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-04-07 |
| RBC Capital | maintain | Sector Perform | Sector Perform | 2025-03-18 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-01-27 |
| Truist Securities | maintain | Buy | Buy | 2025-01-23 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-01-02 |
| Wells Fargo | maintain | Equal Weight | Equal Weight | 2024-12-31 |
| Jefferies | maintain | Buy | Buy | 2024-12-31 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2024-12-20 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2024-12-19 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2024-12-10 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2024-11-14 |
| Barclays | maintain | Overweight | Overweight | 2024-11-14 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2024-11-05 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2024-10-23 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2024-10-22 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2024-08-22 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2024-07-31 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2024-07-24 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2024-05-15 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2024-03-19 |
| RBC Capital | maintain | Sector Perform | Sector Perform | 2024-03-14 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2024-03-13 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2024-02-12 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2024-02-06 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2024-01-19 |